Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Verify the legitimacy of any links or communications from Zealthy to protect your personal information
GLP-1 Targeted Peptide Weight Loss Drugs Market Share, by Distribution Channel, 20242034 Figure 4: U.S
Brain Res Rev 46 : 71117
Intracellular calcium homeostasis and signaling
Retatrutide (LY3437943): Educational Overview Executive Summary Retatrutide is an investigational triple-agonist incretin therapy activating: GLP-1 receptors GIP receptors glucagon receptors This multi-pathway engagement affects: appetite regulation insulin signaling lipid metabolism hepatic glucose handling energy expenditure References: Coskun T et al., Cell Metabolism , 2022 Jastreboff AM et al., NEJM , 2023 Mechanism of Action GLP-1 Receptor Activation GLP-1 signaling: increases glucose-dependent insulin secretion slows gastric emptying activates satiety pathways in the brain Reference: Drucker DJ, Cell Metabolism , 2018 GIP Receptor Activation GIP signaling: enhances insulin secretion improves adipocyte insulin sensitivity modulates lipid metabolism References: Finan B et al., Nature Medicine , 2013 Nauck MA et al., Diabetes Care , 2021 Glucagon Receptor Activation Retatrutide uniquely activates glucagon receptors
Endocrinology 153, 11161128
US$ 23.52
US$ 21.68
US$ 21.60
US$ 24.81
US$ 21.76
US$ 21.99
